1.Bou Bouvard, V et al. (2009) A review of human carcinogens – part B: biological agents. Lancet Oncology 10, 321–322.
2.Schiffman, M et al. (2007) Human papillomavirus and cervical cancer. Lancet 370, 890–907.
3.Bruni, L et al. (2010) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. The Journal of Infectious Diseases 202, 1789–1799.
4.Forman, D et al. (2012) Global burden of human papillomavirus and related diseases. Vaccine 30, F12–F23.
5.Guan, P et al. (2012) Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. International Journal of Cancer 131, 2349–2359.
6.Rodríguez, AC et al. (2010) Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. Journal of the National Cancer Institute 102, 315–324.
7.Kjær, SK et al. (2010) Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. Journal of the National Cancer Institute 102, 1478–1488.
9.Roden, RBS and Stern, PL (2018) Opportunities and challenges for human papillomavirus vaccination in cancer. Nature Reviews Cancer 18, 240–254.
10.Capra, G et al. (2017) Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: a referral hospital-based study in Sicily. Human Vaccines & Immunotherapeutics 13, 1839–1843.
11.Riethmuller, D et al. (2015) Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health 15, 453.
12.de Sanjosé, S et al. (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infectious Diseases 7, 453–459.
13.Massad, LS et al. (2013) 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstetrics & Gynecology 121, 829–846.
14.Nayar, R, Wilbur, D (eds) (2015) The Bethesda System for Reporting Cervical Cytology; Definitions, Criteria, and Explanatory Notes. New York, Dordrecht, London: Springer Cham Heidelberg.
15.Katki, HA et al. (2011) Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncology 12, 663–672.
16.Gu, Y et al. (2016) Genotype distribution characteristics of high-risk human papillomaviruses in women from Shanghai, China. Epidemiology & Infection 144, 1482–1489.
17.Gu, Y et al. (2016) Prevalence characteristics of high-risk human papillomaviruses in women living in Shanghai with cervical precancerous lesions and cancer. Oncotarget 7, 24656–24663.
18.Chan, PK et al. (2014) Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide. PLoS ONE 9, e107573.
19.Berrington de González, A, Sweetland, S and Green, J (2004) Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: a meta-analysis. British Journal of Cancer 90, 1787–1791.
20.Hong, H et al. (2015) Prevalence and genotype distribution of HPV infection among women in Ningbo, China. International Journal of Gynaecology and Obstetrics 131, 96–99.
21.Bao, YP et al. (2008) Human papillomavirus type distribution in women from Asia: a meta-analysis. International Journal of Gynecological Cancer 18, 71–79.
22.Herrero, R et al. (2005) Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. Journal of Infectious Diseases 191, 1796–1807.
23.Cuzick, J et al. (2006) Overview of the European and North American studies on HPV testing in primary cervical cancer screening. International Journal of Cancer 119, 1095–1101.
24.Mayrand, MH et al. (2007) Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. The New England Journal of Medicine 357, 1579–1588.
25.Levi, AW et al. (2016) A comparison of the Roche Cobas HPV test with the hybrid capture 2 test for the detection of high-risk human papillomavirus genotypes. The Archives of Pathology & Laboratory Medicine 140, 153–157.
26.Cox, JT et al. (2003) Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. American Journal of Obstetrics and Gynecology 188, 1406–1412.
27.Stanley, M (2006) Immune responses to human papillomavirus. Vaccine 24, S16–S22.
28.Drolet, M et al. (2015) Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. The Lancet Infectious Diseases 15, 565–580.
29.Saslow, D et al. (2016) Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. A Cancer Journal for Clinicians 66, 375–385.
30.Apter, D et al. (2015) Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clinical and Vaccine Immunology 22, 361–373.
31.Petrosky, E et al. (2015) Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. Morbidity and Mortality Weekly Report 64, 300–304.
32.Dillner, J et al. (2011) Monitoring of human papillomavirus vaccination. Clinical and Experimental Immunology 163, 17–25.